Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization
Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization
复制标题
DOI：
10.1212/wnl.0b013e3181cb3e25
复制
发表时间：
2010-01-19
期刊：
影响因子：
9.9
通讯作者：
Weiner, M. W.
中科院分区：
文献类型：
--
作者：
Petersen, R. C.;Aisen, P. S.;Weiner, M. W.
背景资料：神经影像学指标和化学生物标志物可能是正常衰老和轻度认知功能障碍（MCI）临床进展的重要指标，需要进行纵向评估。目的：对正常对照、轻度认知功能障碍（MCI）患者和轻度阿尔茨海默病（AD）患者的神经影像学指标和化学生物标志物进行横向和纵向的临床评估，以评估神经影像学指标和化学生物标志物指标的实用性。共有819名受试者（229认知正常，398 MCI，192 AD）在基线和随后的12个月使用标准的认知和功能的措施典型的临床试验。结果：MCI的受试者记忆受损比认知正常的受试者，但不损害AD的受试者。MCI受试者的非记忆性认知功能仅受到轻微损害。MCI受试者在12个月内进展为痴呆，每年进展率为16.5%。大约50%的MCI受试者正在接受抗痴呆治疗。对于正常对照受试者，阿尔茨海默病评估量表-认知子量表上有最小的运动，对于MCI为1.1的受试者有轻微的运动，对于AD为4.3的受试者有适度的变化。基线CSF测量A β-42分离3组预期和成功预测12个月的变化，认知measurements.Conclusion：阿尔茨海默病神经影像倡议已成功招募认知正常的受试者，轻度认知障碍（MCI）的受试者，和阿尔茨海默病与预期的基线特征的队列。MCI的12个月进展率与预测一致，CSF指标预示着12个月内临床指标的进展。神经病学（R）2010; 74：201-209
Background: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally.Objective: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease ( AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures.Methods: A total of 819 subjects ( 229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials.Results: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of A beta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures.Conclusion: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment ( MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months. Neurology (R) 2010; 74: 201-209